Nephronomics Receives Investment From CerraCap

The company plans to use the funds to grow its operations and support its development work.

Nephronomics is an AI-driven precision medicine company. It is building a large clinical and genomic dataset focused on cardio-kidney-metabolic (CKM) disease, which connects heart, kidney, and metabolic conditions into one unified model.

Nephronomics uses advanced machine learning to derive useful biological insights from its unique data. Its platform uses tools such as protein modeling, variant prediction, and generative design to identify new disease types, understand their causes, and develop new treatment targets.

Nephronomics’ strength comes from its data—especially in the AI era, where data is more important than models. It has exclusive access to the world’s largest kidney dataset, covering over 42,000 patients across many U.S. dialysis clinics. This scale is hard to match, making the company a leader in data-driven kidney disease innovation.

The opportunity is large, as chronic kidney disease affects 14% of people in the U.S. and about 850 million worldwide. Even with over $141 billion spent each year in the U.S., the disease remains under-researched, leaving room for precision medicine solutions. The company plans to develop its own treatments and to work with pharmaceutical companies to accelerate drug development.

Read More:Octen Closes $10M Seed Funding Round

"This is not simply about applying AI to existing workflows," Vikas Datt, CerraCap leadership, noted. "It's about enabling an entirely new intelligence layer for healthcare and life sciences. Nephronomics will not only accelerate innovation in kidney disease but also demonstrate how the future of medicine will be built on intelligent systems powered by data, driven by insight and scaled through strategic ecosystems."

"CerraCap shares our conviction that the ESKD population represents one of the most genetically informative cohorts in CKM disease — enriched signals of both protective and harmful variants that are uniquely powerful for therapeutic target discovery," said Deniz Kural, Chief Science Officer and Founder of Nephronomics. "Their experience backing applied AI companies and their investment here supports our work translating those signals into precision therapies across the cardio-kidney-metabolic spectrum."

About Nephronomics

Founded in 2023 by Jan Walter, Deniz Kural, Benjamin Hippen, and James Sietstra, Nephronomics is a joint venture between Mechanica Partners and Fresenius Medical Care. It is building one of the world’s largest integrated datasets for cardio-kidney-metabolic (CKM) disease, with over 42,000 patients. The Nephronomics Atlas includes whole-genome data and long-term clinical records, such as lab results, medical history, treatments, and raw radiology images, for patients with advanced kidney disease.

About CerraCap Ventures

Founded in 2015, CerraCap Ventures is an early-stage venture capital firm based in Southern California that invests in B2B enterprise technology. It focuses on digital innovation aligned with its goal of building a healthier and more secure planet. CerraCap helps startups grow quickly by using its Sales & Scale™ model and connecting them with large enterprises to drive revenue.

Read More:BetHog Raises $10M in Series A Funding Led by RockawayX